Routine use of magnetic resonance imaging for early detection of prostate cancer is not justified by the clinical trial evidence Editorial

   

Authors:	Vickers, A.; Carlsson, S. V.; Cooperberg, M.
Title:	Routine use of magnetic resonance imaging for early detection of prostate cancer is not justified by the clinical trial evidence
Abstract:	Guidelines now recommend multiparametric magnetic resonance imaging before prostate biopsy in the work-up for patients with elevated prostate specific-antigen. However, use of magnetic resonance imaging for early detection of prostate cancer is not justified by the clinical trial evidence. © 2020 European Association of Urology
Keywords:	cancer recurrence; cancer patient; nuclear magnetic resonance imaging; sensitivity and specificity; prostate specific antigen; editorial; practice guideline; tumor biopsy; cancer mortality; prostate cancer; gleason score; needle biopsy; prostate biopsy; recurrent disease; transrectal ultrasonography; mortality rate; low risk patient; image guided biopsy; multiparametric magnetic resonance imaging; human; male; priority journal; early cancer diagnosis
Journal Title:	European Urology
Volume:	78
Issue:	3
ISSN:	0302-2838
Publisher:	Elsevier Science, Inc.
Date Published:	2020-09-01
Start Page:	304
End Page:	306
Language:	English
DOI:	10.1016/j.eururo.2020.04.016
PUBMED:	32389443
PROVIDER:	scopus
PMCID:	PMC8327360
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084471842&doi=10.1016%2fj.eururo.2020.04.016&partnerID=40&md5=ba567dfb355d47a4e530410c59041474
Notes:	Editorial -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/169945